PMID- 25373315
OWN - NLM
STAT- MEDLINE
DCOM- 20150622
LR  - 20231213
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 141
IP  - 5
DP  - 2015 May
TI  - Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung 
      cancer: a systematic review and meta-analysis.
PG  - 909-21
LID - 10.1007/s00432-014-1862-5 [doi]
AB  - PURPOSE: Vascular endothelial growth factor signaling pathway plays a crucial 
      role in angiogenesis and has become a promising target for cancer drug 
      development. We aimed to quantify the overall efficacy and safety of angiogenesis 
      inhibitors in advanced non-small cell lung cancer (NSCLC). METHODS: Electronic 
      databases were searched for randomized controlled trials (RCTs) comparing 
      angiogenesis inhibitors with non-angiogenesis inhibitors for NSCLC patients. The 
      extracted data on objective response rates (ORRs), disease control rates (DCRs), 
      progression-free survival (PFS) and overall survival (OS) were pooled. Common 
      adverse events (AEs) were also studied. RESULTS: A total of 33 RCTs involving 
      17,396 patients were included. Compared with non-angiogenesis inhibitors, 
      angiogenesis inhibitors resulted in significant improvement in PFS (HR, 0.81; 95 
      % CI 0.76-0.85; p < 0.001), OS (HR, 0.95; 95 % CI 0.92-0.98; p = 0.004), ORR (RR, 
      1.54; 95 % CI 1.37-1.73; p < 0.001) and DCR (RR, 1.18; 95 % CI 1.10-1.27; p < 
      0.001). The AEs associated with angiogenesis inhibitors were generally 
      predictable and manageable. CONCLUSION: Angiogenesis inhibitors were superior to 
      non-angiogenesis inhibitors in terms of ORR, DCR, PFS and OS in advanced NSCLC 
      patients. Further studies are warranted to explore the predictive biomarkers to 
      pick up those who may gain utmost benefit from anti-angiogenic therapy.
FAU - Hong, Shaodong
AU  - Hong S
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
FAU - Tan, Min
AU  - Tan M
FAU - Wang, Shouzheng
AU  - Wang S
FAU - Luo, Shengyuan
AU  - Luo S
FAU - Chen, Yue
AU  - Chen Y
FAU - Zhang, Li
AU  - Zhang L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20141106
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indazoles)
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Piperidines)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (Quinazolines)
RN  - 0 (Sulfonamides)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7RN5DR86CK (pazopanib)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - NQU9IPY4K9 (cediranib)
RN  - V99T50803M (Sunitinib)
RN  - YO460OQ37K (vandetanib)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Bevacizumab
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology
MH  - Disease-Free Survival
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Indazoles
MH  - Indoles/therapeutic use
MH  - Lung Neoplasms/*drug therapy/metabolism/pathology
MH  - Niacinamide/analogs & derivatives/therapeutic use
MH  - Odds Ratio
MH  - Phenylurea Compounds/therapeutic use
MH  - Piperidines/therapeutic use
MH  - Pyrimidines/therapeutic use
MH  - Pyrroles/therapeutic use
MH  - Quinazolines/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Vascular Endothelial Growth Factor/*antagonists & 
      inhibitors/metabolism
MH  - Signal Transduction/drug effects
MH  - Sorafenib
MH  - Sulfonamides/therapeutic use
MH  - Sunitinib
MH  - Thrombocytopenia/chemically induced
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Ramucirumab
EDAT- 2014/11/07 06:00
MHDA- 2015/06/24 06:00
CRDT- 2014/11/07 06:00
PHST- 2014/08/25 00:00 [received]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2014/11/07 06:00 [entrez]
PHST- 2014/11/07 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - 10.1007/s00432-014-1862-5 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2015 May;141(5):909-21. doi: 10.1007/s00432-014-1862-5. 
      Epub 2014 Nov 6.